These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 28683713)

  • 1. [Non-uremic calciphylaxis due to acenocoumarol].
    Torres-Bondia FI; Parada-Saavedra FJ; Fernández-Armenteros JM; Schoenenberger-Arnaiz JA
    Farm Hosp; 2017 Jul; 41(4):569-570. PubMed ID: 28683713
    [No Abstract]   [Full Text] [Related]  

  • 2. [Sodium thiosulfate for the treatment of acenocumarol-induced calciphylaxis in a patient with preserved kidney function].
    Mateos Egido E; Álamo Medina A; Ródenas Gálvez AC; Lombardero Pin M; Díez Del Pino A
    Farm Hosp; 2017 May; 41(3):425-427. PubMed ID: 28478757
    [No Abstract]   [Full Text] [Related]  

  • 3. Atypical calciphylaxis secondary to treatment with acenocoumarol.
    Alvarez-Pérez A; Gutiérrez-González E; Sánchez-Aguilar D; Toribio J
    Actas Dermosifiliogr; 2012 Jan; 103(1):79-81. PubMed ID: 22444506
    [No Abstract]   [Full Text] [Related]  

  • 4. Acenocoumarol as a risk factor for calciphylaxis: a feature clinicians should be aware of.
    Wenstedt EFE; Huysentruyt CJ; Konings CJAM
    Neth J Med; 2017 May; 75(4):161-164. PubMed ID: 28522774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resolution of acenocoumarol-associated calciphylaxis with drug withdrawal.
    Suárez-Peñaranda JM; Minasyan A; Sainz-Gaspar L; Sánchez-Aguilar MD
    Australas J Dermatol; 2019 Aug; 60(3):e223-e226. PubMed ID: 30790279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Atypical calciphylaxis secondary to treatment with acenocoumarol].
    Alvarez-Pérez A; Gutiérrez-González E; Sánchez-Aguilar D; Toribio J
    Actas Dermosifiliogr; 2012; 103(1):79-81. PubMed ID: 22000587
    [No Abstract]   [Full Text] [Related]  

  • 7. Vitamin K antagonists predispose to calciphylaxis in patients with end-stage renal disease.
    Galloway PA; El-Damanawi R; Bardsley V; Pritchard NR; Fry AC; Ojha SK; Hiemstra TF
    Nephron; 2015; 129(3):197-201. PubMed ID: 25720849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dabigatran in the treatment of a morbidly obese patient with recurring venous thrombosis].
    Callejas Rubio JL; Lara Jiménez MA; Fernández Pugnaire MA; Ortego Centeno N
    Farm Hosp; 2010; 34(2):101. PubMed ID: 20304372
    [No Abstract]   [Full Text] [Related]  

  • 9. [The efficacy and safety of acenocoumarol and warfarin therapy in patients with lower limb deep vein thrombosis].
    Bernát SI; Rókusz L
    Orv Hetil; 2012 May; 153(20):786-90. PubMed ID: 22580505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acenocoumarol associated priapism: report of a case.
    Touloupidis S; Zoumpos I; Kalaitzis C; Vogiatzaki T; Chloropoulou P
    Andrologia; 2004 Feb; 36(1):47-9. PubMed ID: 14871265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abrupt versus gradual withdrawal of vitamin K antagonist treatment in patients with venous thromboembolic disease: assessment of hypercoagulability and clinical outcome.
    de Groot MR; Njo TL; van Marwijk Kooy M; Büller HR
    Clin Lab; 2000; 46(11-12):575-81. PubMed ID: 11109505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction between antiretroviral drugs and acenocoumarol.
    Welzen ME; van den Berk GE; Hamers RL; Burger DM
    Antivir Ther; 2011; 16(2):249-52. PubMed ID: 21447874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. INR variability in anticoagulation with acenocoumarol: is it useful for identifying patients at risk of bleeding and thrombosis?
    Casais P; Sánchez Luceros A; Meschengieser S; Bermejo E; Lazzari MA
    Haematologica; 1999 Aug; 84(8):753-4. PubMed ID: 10457416
    [No Abstract]   [Full Text] [Related]  

  • 14. [Major hemorrhages associated with long-term treatment with acenocoumarol in patients with venous thromboembolic disease in a rural area of Extremadura (Spain)].
    Calvo Romero JM
    Med Clin (Barc); 2005 Jun; 125(2):76-7. PubMed ID: 15970189
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic efficacy of acenocoumarol in a warfarin-resistant patient with deep venous thrombosis: a case report.
    Marusic S; Gojo-Tomic N; Franic M; Bozina N
    Eur J Clin Pharmacol; 2009 Dec; 65(12):1265-6. PubMed ID: 19652960
    [No Abstract]   [Full Text] [Related]  

  • 16. Probable interaction between citalopram and acenocoumarol.
    Borrás-Blasco J; Marco-Garbayo JL; Bosca-Sanleon B; Navarro-Ruiz A
    Ann Pharmacother; 2002 Feb; 36(2):345. PubMed ID: 11847961
    [No Abstract]   [Full Text] [Related]  

  • 17. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism.
    Wawrzyńska L; Tomkowski WZ; Przedlacki J; Hajduk B; Torbicki A
    Pathophysiol Haemost Thromb; 2003; 33(2):64-7. PubMed ID: 14624046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic idiopathic urticaria successfully treated by anticoagulant drugs.
    Spring P; Angelillo-Scherrer A; Bigliardi P
    Eur J Dermatol; 2012; 22(6):788-90. PubMed ID: 23178180
    [No Abstract]   [Full Text] [Related]  

  • 19. [Effectiveness and safety of oral anticoagulation treatment with acenocoumarol in non-valvular atrial fibrillation].
    Castro C; Bustos L; Ocampo R; Molina E; Cabrero P; Vergara R; Lanas F
    Rev Med Chil; 2017 Oct; 145(10):1243-1251. PubMed ID: 29488564
    [No Abstract]   [Full Text] [Related]  

  • 20. Probable interaction between acenocoumarol and levofloxacin: a case series.
    Palacios-Zabalza I; Bustos-Martínez M; Peral-Aguirregoitia J; Martínez-Bengoechea MJ; Aguirre Gomez C
    J Clin Pharm Ther; 2015 Dec; 40(6):693-5. PubMed ID: 26394892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.